Topical calcipotriol treatment in advanced breast cancer.
19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100 micrograms daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.
Bower
M
M
Department of Cellular and Molecular Sciences, St. George's Hospital Medical School, London.
Colston
K W
KW
Stein
R C
RC
Hedley
A
A
Gazet
J C
JC
Ford
H T
HT
Combes
R C
RC
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D008875:Middle Aged; D018167:Receptors, Calcitriol; D011960:Receptors, Estrogen / Q000187:drug effects; D011987:Receptors, Steroid / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary
D018167:Receptors, Calcitriol; D011960:Receptors, Estrogen; D011987:Receptors, Steroid; C055085:calcipotriene; D002117:Calcitriol